BPC-157 actively reduces inflammation throughout the body, making it an excellent treatment for conditions like tendonitis, arthritis, and overuse injuries
The use the FDA is actually evaluating for BPC-157 is ulcerative colitis, an inflammatory bowel condition, a holdover from the molecules distant origins in gut research decades ago
The research-grade Tesamorelin supplied here sits outside both: it is a chemically synthesized reference compound documented through HPLC, LC-MS, amidation, and endotoxin testing for in vitro laboratory work only, with no patient-directed preparation, prescription pathway, or pharmacy dispensing workflow attached
This approach maximizes BPC-157's local effects while ensuring TB-500's systemic benefits reach all tissues
The side effects: Both are generally safe, with potential for pain at injection site, swelling, and a low risk of infection